By Melissa Wildstein | President & Founder, The Matchstick Group | 15+ years in medical device marketing
Last Updated: March 2026
A medical device brand name is a commercial asset—one that signals clinical credibility, supports regulatory compliance, survives IP screening, and gives your sales team something a clinician or procurement officer will actually remember. Choosing the wrong name doesn’t just create a branding problem. It creates a legal problem, a regulatory problem, and a sales problem, often at the worst possible moment in your launch timeline.
Most medtech companies underestimate what it takes to name a medical device well. They approach it like a consumer product exercise—generating names in a conference room, running a quick Google search, and choosing whatever feels right to the founding team.
What they discover later, sometimes after clearance, sometimes after launch, is that the name is already trademarked in a relevant class, that clinicians can’t pronounce it, that it makes an unsubstantiated claim, or that it simply doesn’t hold up when a hospital procurement committee looks it up for the first time.
This guide covers what separates a strong medical device name from a weak one, the dimensions every name must be evaluated against, and how The Matchstick Group approaches naming through our proprietary STRIKE Method™.
For the broader launch framework this fits into, see our Complete Guide to Medical Device Product Launch Marketing. If you’re building your go-to-market strategy alongside your naming work, our guide to Go-to-Market Strategy for a Class II Medical Device is a useful complement.
Why Medical Device Naming Is Not a Consumer Branding Exercise
The naming conventions that work in consumer products—evocative, emotional, aspirational —often fail in medtech, for reasons that are structural, not stylistic. Medical device naming operates under a set of constraints that most brand consultancies outside the industry simply don’t account for.
Regulatory constraints shape what you can say
A medical device name cannot make a claim that goes beyond the device’s cleared or approved indications for use. If your name implies a clinical outcome that isn’t substantiated by your labeling—even implicitly—you have a compliance problem before your first sales call.
FDA’s guidance on promotional labeling applies to your brand name as much as it applies to your advertising copy. This means names that lean on superlatives (“OptiMax,” “PerfectSeal”) or outcome implications (“CurePoint,” “HealFast”) carry more regulatory risk than they’re worth.
Intellectual property is more complex than most companies expect
Medical device companies typically need to conduct trademark clearance searches across multiple USPTO classes—not just Class 10 (medical and surgical instruments) but adjacent classes covering software, services, and distribution. A name that clears a basic search can still face opposition from a holder in a related class, particularly in the cardiovascular, orthopedic, or diagnostic imaging spaces where the trademark landscape is dense.
International clearance adds another layer: a name that’s available in the U.S. may be registered in the EU, Japan, or key distributor markets.
Your audience is not one person
Consumer naming targets a relatively homogeneous audience with a relatively simple purchase journey. Medical device naming must work for an audience that includes interventional cardiologists, OR nurses, VAC committee members, hospital procurement officers, C-suite executives, and in some cases, patients.
A name that resonates powerfully with a clinician may fall flat with a CFO. A name that sounds technically credible to an engineer may feel cold and unapproachable to the clinical staff who will interact with it daily.
The best medical device names thread this needle—clinical enough to be credible, accessible enough to be memorable.
The name has to survive the sales process
Your brand name will appear on business cards, in hospital formularies, on device labels, in RFP responses, and in the mouth of a sales rep who’s pitching a surgeon between cases. It needs to be easy to say, easy to spell, and easy to remember in a context where attention is scarce and skepticism is high.
Names that require explanation, that are routinely mispronounced, or that look awkward in a regulated label format create friction at every point in the commercial process.
What Makes a Medical Device Name Commercially Effective?
Across more than 50 medical device naming engagements, The Matchstick Group has identified six dimensions that consistently separate names that sell from names that stall. No name scores perfectly on all six—but the strongest names score well on most, and critically high on the ones that matter most for their specific category and buyer.
- Pronounceability: If your sales rep has to correct a clinician who’s mispronouncing the name, that’s a failure. Names should be intuitive to say in English—and ideally in the primary international markets where you’ll sell. One-syllable and two-syllable names have a structural advantage in clinical environments where communication is rapid and high-stakes.
- Memorability: A name that doesn’t stick is a name that doesn’t get recalled at the moment of purchase. Memorability is driven by distinctiveness, brevity, and phonetic structure. Names that are moderately novel—familiar enough to feel credible, different enough to stand out—tend to outperform both generic descriptors and aggressively invented names.
- Credibility: In medtech, credibility is often conveyed through name architecture rather than the name itself. A name that fits logically within a parent company’s portfolio, that uses stems or suffixes consistent with category conventions, or that evokes precision and science signals competence. Credibility doesn’t mean boring—it means the name earns trust on first encounter.
- Regulatory defensibility: This is the dimension most naming processes underweight. A strong name stays within the bounds of what your cleared indications allow. It avoids implied claims. It doesn’t borrow clinical terminology in ways that could be read as off-label. It’s reviewed through your MLR process before it goes on a single piece of collateral.
- Trademark clearance runway: A name is only an asset if you can own it. Trademark clearance is not a one-step process—it requires searches across relevant USPTO classes, a freedom-to-operate analysis, and, in many cases, international clearance. The strongest names are those that have clear runway: limited conflicts, no aggressive adjacencies, and the ability to be registered in the classes and geographies that matter for your commercial model.
- Brand architecture fit: A product name doesn’t exist in isolation. It lives within a corporate brand, alongside other products, sub-brands, and potentially a platform or portfolio. A name that fits elegantly within your existing brand architecture is easier to launch, easier to extend, and easier to manage over the device’s commercial lifecycle.
The STRIKE Method™: TMG’s Proprietary Approach to Medical Device Naming
Most naming processes generate options and ask clients to pick one. The STRIKE Method™ is different. It’s a structured, six-phase naming system built specifically for the medtech environment—one that integrates buyer psychology, linguistic analysis, IP screening, and real-world commercial stress testing before a single name is presented for consideration.
Here’s what each phase involves at a high level, and why it matters.
S
Stakeholder Empathy Mapping
Naming that sells starts with a rigorous understanding of who you’re selling to — not just the primary clinical user, but the full decision-making unit that touches the purchase. In the STRIKE Method™, we begin by mapping buyer psychology across all relevant stakeholders: clinicians, procurement officers, C-suite decision-makers, and, where relevant, investors, distributors, and channel partners. We’re not just asking what they want to hear. We’re identifying the trust gaps, the credibility signals, and the linguistic cues that move each audience from awareness to preference. This phase ensures the naming brief is grounded in real commercial dynamics, not assumptions about who the buyer is or what they care about.
T
Terminology Mining
Before generating name candidates, we build what we call a Root Bank — a structured library of linguistic raw material drawn from the clinical, scientific, and technical vocabulary of your specific device category. This isn’t a brainstorm. It’s a systematic extraction of the semantic field your name will live in: the terminology clinicians use at the point of care, the language your competitors have already claimed, the scientific stems that convey precision and category credibility, and the linguistic fingerprint that is authentic to your company and your technology. The Root Bank becomes the generative foundation for every name candidate we develop.
R
Resonance Architecture
With the Root Bank established, we generate a broad candidate pool—typically 150 to 200 names across multiple strategic directions. These aren’t random variations; each candidate is developed against a specific naming strategy, whether that’s a descriptive approach, an evocative approach, a coined term, or a structural derivation. Candidates are then evaluated against what we call the Resonance Matrix—a scoring framework that assesses each name across the six commercial dimensions described above. This phase narrows the field to a curated shortlist of names that are not just creative, but commercially defensible.
I
IP & Regulatory Runway
Every name on the shortlist goes through a structured IP and regulatory screening before it’s presented to the client. On the IP side, this means searching across the USPTO classes most relevant to medical devices and adjacent services, assessing the risk profile of any conflicts, and evaluating international clearance requirements in priority markets. On the regulatory side, we review each candidate against FDA promotional guidance and the device’s cleared indications to flag any names that carry implied claims or labeling risk. Names that don’t have clear runway are eliminated—not deprioritized, eliminated—before the client presentation.
K
Kinetic Stress Testing
A name that looks good on a spreadsheet may not survive contact with the real world. In the Kinetic Stress Testing phase, we pressure-test the shortlisted names against the actual commercial contexts in which they’ll be used. This includes qualitative feedback from buyer personas representative of your target audience, a competitive shelf test that evaluates how each name performs alongside existing competitors in the category, and practical stress tests for pronunciation, spelling, and recall. The goal is to surface names that hold up—not just in a conference room, but on the floor of a hospital, in a distributor conversation, and in a VAC presentation.
E
Elevation & Handoff
The final phase is where the name becomes an asset. We deliver a structured naming presentation that includes the recommended name, the strategic rationale, the IP clearance summary, and a brand architecture brief that shows how the name fits within your corporate and product portfolio. We also develop the narrative that your team will use to introduce the name to internal stakeholders, investors, and commercial partners—because how you tell the story of why you chose this name matters almost as much as the name itself. The deliverable includes a full legal handoff brief for trademark filing and any follow-on international registration.
Common Medical Device Naming Mistakes—and How to Avoid Them
Even companies that invest in naming often make the same avoidable mistakes. Here are the ones we see most frequently, and what to do instead.
- Letting the founding team name the device in a conference room. Internal teams are too close to the product and too far from the buyer. The names that emerge from internal brainstorms tend to be technically accurate and commercially inert. Naming requires external perspective, structured methodology, and distance from the engineering mindset.
- Skipping IP screening until after the name is in use. We’ve worked with companies that had already printed booth materials, filed their 510(k), and begun sales conversations when they discovered their product name was already trademarked. Trademark conflicts discovered post-launch are expensive to resolve and reputationally damaging. IP clearance is not the last step—it’s integrated throughout.
- Optimizing for the founding team’s preference instead of the buyer’s psychology. The name you love internally is often the name that performs worst externally. A name that the CMO finds elegant may be invisible to a VAC committee. A name the engineers love for its technical precision may mean nothing to a purchasing officer. Buyer-centric naming requires setting aside internal preferences and anchoring to the audience.
- Choosing a name that can’t scale. A product name that works for your first indication may create problems when you expand your cleared uses, add a product line, or move into new geographies. Think about name architecture from the beginning—not just what this name needs to do today, but what it needs to accommodate in three to five years.
- Treating naming as a branding exercise rather than a commercial one. The best medical device names are commercial tools. They’re built to support the sales conversation, to signal the right things to the right audiences, and to create a distinctive position in a crowded category. If your naming process doesn’t start with the commercial objective, it’s unlikely to end with a commercially effective name.
How to Know When You Have the Right Name
There’s no single test that tells you a medical device name is right—but there are reliable signals that you’re close.
The right name passes the clinical hallway test. Say it out loud. Say it fast. Could a rep say it while walking into an OR suite? Could a nurse write it down correctly after hearing it once? If the answer is no, keep looking.
The right name doesn’t require explanation. If your sales team has to explain what the name means before they can talk about what the device does, the name is doing negative work. A strong name either communicates something useful on its own, or it gets out of the way and lets the device speak.
The right name has runway. It’s cleared in the trademark classes you need, it’s available in the international markets on your commercial roadmap, and it doesn’t create conflicts with competitors you’ll be selling against. If your IP attorney is nervous, that’s a signal worth heeding.
The right name fits the portfolio. It works alongside your corporate brand and your other products without creating confusion or inconsistency. It contributes to a coherent brand architecture rather than fragmenting it.
And finally—the right name travels well. It works in a press release, on a trade show booth, on the side of a device, in a 60-second sales pitch, and in a purchasing committee recommendation. Names that only work in one context are not the right name.
Frequently Asked Questions
When in the product development process should we start naming a medical device?
How long does it take to name a medical device?
Do we need a trademark attorney for medical device naming?
Can our medical device name make clinical claims?
What's the difference between a product name and a platform name in medtech?
Ready to Name Your Medical Device the Right Way?
At The Matchstick Group, naming is one of the most consequential commercial decisions we help medtech companies make—and one of the most frequently underinvested. Our STRIKE Method™ gives you a name that’s built to sell, built to withstand IP scrutiny, and built to grow with your device and your company.
Whether you’re launching a first product, extending a platform, or rebranding a legacy device, our Launch and Accelerate programs integrate naming into the full commercial buildout.
Schedule a call to talk through your naming challenge and how the STRIKE Method™ can help.
